Fertavid

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

follitropin beta

Available from:

Merck Sharp & Dohme B.V. 

ATC code:

G03GA06

INN (International Name):

follitropin beta

Therapeutic group:

Sex hormones and modulators of the genital system,

Therapeutic area:

Infertility; Hypogonadism

Therapeutic indications:

In the female:Fertavid is indicated for the treatment of female infertility in the following clinical situations:Anovulation (including polycystic ovarian disease, PCOD) in women who have been unresponsive to treatment with clomifene citrateControlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs [e.g. in vitro fertilisation/embryo transfer (IVF/ET), gamete intra-fallopian transfer (GIFT) and intracytoplasmic sperm injection (ICSI).In the male:Deficient spermatogenesis due to hypogonadotrophic hypogonadism.

Product summary:

Revision: 12

Authorization status:

Withdrawn

Authorization date:

2009-03-19

Patient Information leaflet

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
Лекарствен продукт с невалидно
разрешение за употреба
2
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Fertavid 50 IU/0,5 ml инжекционен разтвор
Fertavid 75 IU/0,5 ml инжекционен разтвор
Fertavid 100 IU/0,5 ml инжекционен разтвор
Fertavid 150 IU/0,5 ml инжекционен разтвор
Fertavid 200 IU/0,5 ml инжекционен разтвор
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Fertavid 50 IU/0,5 ml инжекционен разтвор
Един флакон съдържа 50 IU рекомбинантен
фоликулостимулиращ хормон (ФСХ) в 0,5 ml
воден разтвор. Това съответства на
количество в дозова единица от 100 IU/ml.
Един флакон
съдържа 5 микрограма протеин
(специфичната _in vivo_ биологична
активност се равнява
приблизително на 10 000 IU ФСХ / mg протеин).
Инжекционният разтвор съдържа
активното
вещество фолитропин бета (follitropin beta),
произведен чрез генно инженерство в
клетъчна
линия от яйчник на китайски хамстер
(ЯКХ).
Fertavid 75 IU/0,5 ml инжекционен разтвор
Един флакон съдържа 75 IU рекомбинантен
фоликулостимулиращ хормон (ФСХ) в 0,5 ml
воден разтвор. Това съответства на
количество в дозова единица от 150 IU/ml.
Един флакон
съдържа 7,5 микрограма протеин
(специфичната _in vivo_ биологична
активност се равнява
приблизително на 10 000 IU ФСХ / mg п
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
Лекарствен продукт с невалидно
разрешение за употреба
2
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Fertavid 50 IU/0,5 ml инжекционен разтвор
Fertavid 75 IU/0,5 ml инжекционен разтвор
Fertavid 100 IU/0,5 ml инжекционен разтвор
Fertavid 150 IU/0,5 ml инжекционен разтвор
Fertavid 200 IU/0,5 ml инжекционен разтвор
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Fertavid 50 IU/0,5 ml инжекционен разтвор
Един флакон съдържа 50 IU рекомбинантен
фоликулостимулиращ хормон (ФСХ) в 0,5 ml
воден разтвор. Това съответства на
количество в дозова единица от 100 IU/ml.
Един флакон
съдържа 5 микрограма протеин
(специфичната _in vivo_ биологична
активност се равнява
приблизително на 10 000 IU ФСХ / mg протеин).
Инжекционният разтвор съдържа
активното
вещество фолитропин бета (follitropin beta),
произведен чрез генно инженерство в
клетъчна
линия от яйчник на китайски хамстер
(ЯКХ).
Fertavid 75 IU/0,5 ml инжекционен разтвор
Един флакон съдържа 75 IU рекомбинантен
фоликулостимулиращ хормон (ФСХ) в 0,5 ml
воден разтвор. Това съответства на
количество в дозова единица от 150 IU/ml.
Един флакон
съдържа 7,5 микрограма протеин
(специфичната _in vivo_ биологична
активност се равнява
приблизително на 10 000 IU ФСХ / mg п
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 23-06-2020
Summary of Product characteristics Summary of Product characteristics Bulgarian 23-06-2020
Public Assessment Report Public Assessment Report Bulgarian 23-06-2020
Patient Information leaflet Patient Information leaflet Spanish 23-06-2020
Public Assessment Report Public Assessment Report Spanish 23-06-2020
Patient Information leaflet Patient Information leaflet Czech 23-06-2020
Public Assessment Report Public Assessment Report Czech 23-06-2020
Patient Information leaflet Patient Information leaflet Danish 23-06-2020
Public Assessment Report Public Assessment Report Danish 23-06-2020
Patient Information leaflet Patient Information leaflet German 23-06-2020
Public Assessment Report Public Assessment Report German 23-06-2020
Patient Information leaflet Patient Information leaflet Estonian 23-06-2020
Public Assessment Report Public Assessment Report Estonian 23-06-2020
Patient Information leaflet Patient Information leaflet Greek 23-06-2020
Public Assessment Report Public Assessment Report Greek 23-06-2020
Patient Information leaflet Patient Information leaflet French 23-06-2020
Public Assessment Report Public Assessment Report French 23-06-2020
Patient Information leaflet Patient Information leaflet Italian 23-06-2020
Public Assessment Report Public Assessment Report Italian 23-06-2020
Patient Information leaflet Patient Information leaflet Latvian 23-06-2020
Public Assessment Report Public Assessment Report Latvian 23-06-2020
Patient Information leaflet Patient Information leaflet Lithuanian 23-06-2020
Summary of Product characteristics Summary of Product characteristics Lithuanian 23-06-2020
Public Assessment Report Public Assessment Report Lithuanian 23-06-2020
Patient Information leaflet Patient Information leaflet Hungarian 23-06-2020
Summary of Product characteristics Summary of Product characteristics Hungarian 23-06-2020
Public Assessment Report Public Assessment Report Hungarian 23-06-2020
Patient Information leaflet Patient Information leaflet Maltese 23-06-2020
Public Assessment Report Public Assessment Report Maltese 23-06-2020
Patient Information leaflet Patient Information leaflet Dutch 23-06-2020
Public Assessment Report Public Assessment Report Dutch 23-06-2020
Patient Information leaflet Patient Information leaflet Polish 23-06-2020
Public Assessment Report Public Assessment Report Polish 23-06-2020
Patient Information leaflet Patient Information leaflet Portuguese 23-06-2020
Summary of Product characteristics Summary of Product characteristics Portuguese 23-06-2020
Public Assessment Report Public Assessment Report Portuguese 23-06-2020
Patient Information leaflet Patient Information leaflet Romanian 23-06-2020
Public Assessment Report Public Assessment Report Romanian 23-06-2020
Patient Information leaflet Patient Information leaflet Slovak 23-06-2020
Public Assessment Report Public Assessment Report Slovak 23-06-2020
Patient Information leaflet Patient Information leaflet Slovenian 23-06-2020
Summary of Product characteristics Summary of Product characteristics Slovenian 23-06-2020
Public Assessment Report Public Assessment Report Slovenian 23-06-2020
Patient Information leaflet Patient Information leaflet Finnish 23-06-2020
Public Assessment Report Public Assessment Report Finnish 23-06-2020
Patient Information leaflet Patient Information leaflet Swedish 23-06-2020
Public Assessment Report Public Assessment Report Swedish 23-06-2020
Patient Information leaflet Patient Information leaflet Norwegian 23-06-2020
Summary of Product characteristics Summary of Product characteristics Norwegian 23-06-2020
Patient Information leaflet Patient Information leaflet Icelandic 23-06-2020
Summary of Product characteristics Summary of Product characteristics Icelandic 23-06-2020
Patient Information leaflet Patient Information leaflet Croatian 23-06-2020

Search alerts related to this product

View documents history